Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)

Vaccine

Volumn 30, Issue 50, 2012, Pages 7253-7259

  Loughlin, Anita M ^a,b   Marchant, Colin D ^a   Adams, William ^a   Barnett, Elizabeth ^a   Baxter, Roger ^c   Black, Steve ^d   Casey, Christine ^e   Dekker, Cornelia ^f   Edwards, Katherine M ^g   Klein, Jerold ^a   Klein, Nicola P ^c   LaRussa, Philip ^h   Sparks, Robert ^g   Jakob, Kathleen ^h  

^a BOSTON MEDICAL CENTER   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c KAISER PERMANENTE   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g VANDERBILT UNIVERSITY   (United States)

^h NewYork Presbyterian Hospital   (United States)

Author keywords

Causality; Vaccine safety; VAERS

Indexed keywords

VACCINE;

ANAPHYLAXIS; ARTHRITIS; ARTICLE; AUTISM; CARDIOPULMONARY ARREST; DEATH; DEPRESSION; FATALITY; FEVER; GUILLAIN BARRE SYNDROME; HEMOLYTIC UREMIC SYNDROME; HEPATITIS; HUMAN; HYPERSENSITIVITY; IMMUNIZATION; INJECTION SITE PAIN; INJECTION SITE REACTION; LEUKOCYTOSIS; LYME DISEASE; MEDICAL RECORD; PNEUMONIA; PRIORITY JOURNAL; SEIZURE; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TELECONSULTATION; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CAUSALITY; CHILD; CHILD, PRESCHOOL; DRUG TOXICITY; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; VACCINES; YOUNG ADULT;

EID: 84869870964     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.074     Document Type: Article

References (32)

1. Hill A.B. The environment and disease: association or cause?. Proc R Soc Med 1965, 58:295-300.
2. Rothman K.J., Greenland S. Causation and causal inference. Modern epidemiology 1998, 24-28. Lippincott-Raven Publishers, Philadelphia, PA. second ed. K.J. Rothman, S. Greenland (Eds.).
3. Institutes of Medicine Adverse effects for vaccines: evidence and causality 2011, National Academies Press, Washington, DC.
4. Institutes of Medicine Vaccine safety research data access and public trust 2005, National Academies Press, Washington, DC.
5. Institutes of Medicine Immunization safety review: vaccine and autism 2004, National Academies Press, Washington, DC.
6. Institutes of Medicine Immunization safety review: influenza vaccine and neurological complications 2004, National Academies Press, Washington, DC.
7. Institutes of Medicine Immunization safety review: vaccinations and sudden infant death in infancy 2003, National Academies Press, Washington, DC.
8. Institutes of Medicine Immunization safety review: hepatitis B vaccine and demyelinating neurological disorders 2002, National Academies Press, Washington, DC.
9. Institutes of Medicine Immunization safety review: immunization and immune dysfunction 2002, National Academies Press, Washington, DC.
10. Institutes of Medicine Immunization safety review: thimerosol-containing vaccines and neurodevelopmental disorders 2001, National Academies Press, Washington, DC.
11. Institutes of Medicine Immunization safety review: measles-mumps-rubella vaccine and autism 2001, National Academies Press, Washington, DC.
12. National Childhood Vaccine Injury Act of 1986, at Section 2125 of the Public Health Service Act as codified at 42 U.S.C. Section 300-26.
13. Miller E.R., Haber P., Hibbs B., Broder K. Surveillance for adverse events following immunization using the Vaccine Adverse Event Reporting System (VAERS). Vaccine preventable disease surveillance manual 2011, [Chapter 21, accessed 07.11.11]. http://cdc.gov/vaccines/pubs/surv-manual/chpt21-surv-adverse-events.pdf, 5th ed.
14. Varricchio F., Iskander J., Destefano F., Ball R., Pless R., Braun M.M., et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004, 23(4):287-294.
15. Ball L.K., Ball R., Gellin B.G. Developing safe vaccines. New generation vaccines 2004, 127-144. Marcel Dekker, Inc., New York. third ed., revised and expanded. M.M. Levine, J.B. Kaper, R. Rappuoli, M.A. Liu, M.F. Good (Eds.).
16. Singleton J.A., Lloyd J.C., Mootrey G.T., Salive M.E., Chen R.T. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. Vaccine 1999, 17:2908-2917.
17. ® Meningococcal conjugate vaccine-United States, June-July 2005. MMWR 2005, 54(40):1023-1025.
18. ® Meningococcal conjugate vaccine-United States, October 2005-February 2006. MMWR 2006, 55(13):364-366.
19. ® Meningococcal conjugate vaccine-United States, June 2005-September 2006. MMWR 2006, 55(41):1120-1124.
20. LaRussa P.S., Edwards K.M., Dekker C.L., Klein N.P., Halsey N.A., Marchant C., et al. Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network. Pediatrics 2011, 127(May (Suppl. 1)):S65-S73. [Epub 2011 April 18].
21. Rosenberg M., Sparks R., McMahon A., Iskander J., Campbell J.D., Edwards K.M. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age. Vaccine 2009, 27(32):4278-4283.
22. Williams S.E., Pahud B.A., Vellozzi C., Donofrio P.D., Dekker C.L., Halsey N., et al. Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination. Vaccine 2011, 29(46):8302-8308.
23. Collet J.P., MacDonald N., Cashman N. Monitoring signals of vaccine safety: the assessment of individual adverse events reports by and expert advisory panel. Bull World Health Organization 2000, 78(2):178-185. Pless and the Advisory Committee on Causality Assessment.
24. WHO. Adverse event following immunization (AEFI): causality assessment. [accessed 07.08.08]. http://www.who.int/vaccines-documents/DocsPDF05/815.pdf.
25. Williams S.E., Klein N.P., Halsey N., Dekker C.L., Baxter R.P., Marchant C.D., et al. Overview of the Clinical Consult Case Review of adverse events following immunization: Clinical Immunization Safety Assessment (CISA) network 2004-2009. Vaccine 2011, 29(40):6920-6927.
26. VAERS data. [accessed January 2005]. http://vaers.hhs.gov/data/data.
27. Food and Drug Administration 21 CFR Part 600.80. Postmarketing reporting of adverse experiences. Federal Register 1997, 62:52252-52253.
28. Stratton K.R., Howe C.J., Johnston R.B. Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. JAMA 1994, 271(20):1602-1605.
29. WHO. Causality assessment of adverse events following immunizations. Global Advisory Committee on Vaccine Safety, WER 23 March 2001. [accessed 18.03.08]. http://www.who.int/vaccine_safety/causality/en.
30. US Department of Health and Human Services National Vaccine Plan: protecting the Nation's health through immunization 2010, [accessed October 2011]. http://www.hhs.gov/nvpo/vacc_plan/2010%20Plan/nationalvaccineplan.pdf.
31. Bonhoeffer J., Heininger U., Kohl K., Chen R.T., Duclos P., Heijbel H., et al. Standardized case definitions of adverse events following immunization (AEFI). Vaccine 2004, 22(5-6):547-550.
32. Pahud B. Dekker CL, Halsey N, LaRussa P, Baxter R, Klein N, et al. Clinical assessment of serious adverse events following 2009 H1N1 vaccination in children. Poster 1364 presented at: The 48th Annual Meeting of the Infectious Diseases Society of America (IDSA), October 21-24, 2010, Vancouver, Canada.